Overview

A Comparison of the Drug Telbivudine (LdT) and Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis.

Status:
Completed

Trial end date:
2007-08-01

Target enrollment:

Participant gender:

Summary

This trial is being done to see if the investigational drug, LdT (Telbivudine), is safe and effective in the treatment of hepatitis B infection. In addition to this, we will be looking at the comparison of the effects (good and bad) of LdT and lamivudine.

Phase:

Phase 3

Details

Lead Sponsor:

Mayo Clinic

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Lamivudine
Telbivudine